Public market insider buying at Cybin (E:CYBN)

Aaron Frank Bartlone, a Subsidiary Executive, acquired 59,999 Common Shares on a direct ownership basis at a price of $1.620USD on November 22nd, 2021. This represents a $123,248 investment into the company's shares and an account share holdings change of 9.4%.

Cybin is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Cybin Inc. is a Canada-based biopharmaceutical company. The Company is focused on progressing psychedelic therapeutics. The Company operates business through its subsidiary Cybin Corp. The Company operates through two segments: Serenity Life Sciences Inc. (Serenity Life) and Cybin US Holdings Inc. (Cybin U.S.) that focus on the research and development of psychedelic pharmaceutical products, and Natures Journey Inc. that focuses on consumer mental wellness, including non-psychedelic nutraceutical products. The Company focuses on the development of treatment regimens consisting of psychedelic molecules and related clinical protocols. Its subsidiaries include Natures Journey Inc. (Journey), Serenity Life Sciences Inc. (Serenity), Cybin US Holdings Inc. (Cybin US), Adelia Therapeutics Inc. (Adelia) and Cybin IRL Limited.